Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors.
Journal: ACS chemical neuroscience
Published: December 02, 2021
Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study.
Journal: Molecular cancer therapeutics
Published: November 26, 2019
Isolevuglandins as a gauge of lipid peroxidation in human tumors.
Journal: Free radical biology & medicine
Published: September 24, 2016
Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.
Journal: Bioorganic & medicinal chemistry letters
Published: September 02, 2016
Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.
Journal: Journal of medicinal chemistry
Published: August 03, 2016
Showing 1-6 of 6
Last Updated: 09/26/2026